Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net revenue was $38,908,000 compared with $13,574,000 a year ago. Loss from operations was $13,964,000 against $14,360,000 a year ago. Loss before provision for income taxes was $24,747,000 compared with $19,351,000 a year ago. Net loss was $24,568,000 against $19,920,000 a year ago. Basic and diluted net loss per share was $1.32 compared with $1.48 a year ago. Non-GAAP net loss was $3,317,000 against $20,094,000 a year ago. Non-GAAP basic net loss per share was $0.18 against $1.50 a year ago. On a pro forma basis, net loss in the fourth quarter of 2017 was $3.3 million, compared to $20.1 million for the same period in 2016. For the full year, the company reported net revenue was $138,438,000 compared with $13,574,000 a year ago. Loss from operations was $86,798,000 against $36,706,000 a year ago. Loss before provision for income taxes was $126,127,000 compared with $52,405,000 a year ago. Net loss was $126,710,000 against $52,870,000 a year ago. Basic and diluted net loss per share was $6.81 compared with $4.69 a year ago. Non-GAAP net loss was $30,018,000 against $135,985,000 a year ago. Non-GAAP basic net loss per share was $1.61 against $12.05 a year ago. On a pro forma basis, net loss for the year ended December 31, 2017 was $30.0 million, compared to $136.0 million in 2016.